Dana-Farber Cancer Institute | Strategic Alliance Partners

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss how ADCs could continue to reshape ovarian cancer management.

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Mittendorf discusses her priorities for advancing patient care and supporting up-and-coming oncology professionals during her 2026-2027 ASCO presidency.

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.